ORIC PHARMACEUTICALS INC
ORICNASDAQTrading Snapshot
- Day Range
- $910.20 – $926.22
- 52-Week Range
- $7.23 – $14.93
- Volume
- $1.96B
- Avg Volume
- $1.72B
- Shares Outstanding
- 103.5M
- Next Earnings
- Nov 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $128M
- Last Q Revenue
- $35M
- P/E Ratio
- -9.8
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.30
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +24.3%
Why Investors Own ORIC
- ✓High-growth profile — revenue up -2.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ORIC PHARMACEUTICALS INC
ORIC
StockOtter · stockotter.spaceAbout ORIC PHARMACEUTICALS INC
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
ORIC PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ORIC price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ORIC PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.